Quidel Corporation - News Releases

2019 2018 2017 2016 2015 2014

12/21/2017

Quidel Receives FDA Clearance and CLIA Waiver for Its Point-of-Care Sofia® 2 Instrument for Use with Sofia Strep A+ Assay

12/21/2017

Quidel Receives FDA Clearance for Its New Solana® Molecular Assay for the Detection of Group B Streptococcal Infections

12/21/2017

Quidel to Present at 36th Annual J.P. Morgan Healthcare Conference

12/19/2017

Quidel Files Form 8-K/A, Reports Historical and Pro Forma Financial Information for Acquired Triage Assets and Combined Quidel and Triage Businesses

12/13/2017

Quidel Announces Timing of Filing of Form 8-K/A To Report Historical and Pro Forma Financial Information for Acquired Triage Assets and Combined Quidel and Triage Businesses

11/27/2017

Quidel Confident in Legal Strength and Validity of Supply Agreement with Beckman Coulter to Sell BNP Assay Assets

11/15/2017

Quidel to Present at the 29th Annual Piper Jaffray Healthcare Conference

11/01/2017

Quidel Reports Third Quarter 2017 Financial Results

10/23/2017

Quidel Receives FDA Clearance for Its Point-of-Care Sofia® Lyme FIA

10/17/2017

Quidel Receives FDA Clearance for Its Solana® RSV + hMPV Assay

10/13/2017

Quidel to Hold Third Quarter 2017 Financial Results Conference Call on November 1, 2017

10/06/2017

Quidel Announces Closing of Acquisition of Alere Triage® Assets Creating an Expanded Portfolio of Rapid Diagnostic Capabilities in Critical Care Settings

09/28/2017

Quidel Announces Early Termination of the Hart-Scott-Rodino Waiting Period for Its Pending Acquisition of Alere’s Triage® B-type Naturietic Peptide (BNP) Assay Business Run on Beckman Coulter Analyzers

09/18/2017

Quidel Announces Revised Agreement for Its Pending Acquisition of Alere’s B-type Naturietic Peptide (BNP) Assay Business Run on Beckman Coulter Analyzers

09/08/2017

Quidel to Participate in the CEO Series Conference Call Hosted by Canaccord Genuity

07/31/2017

Quidel to Present at the 37th Annual Canaccord Genuity Growth Conference

07/26/2017

Quidel Reports Second Quarter 2017 Financial Results

07/17/2017

Quidel Announces Definitive Agreement to Acquire Alere Triage® Assets

07/14/2017

Quidel to Hold Second Quarter 2017 Financial Results Conference Call on July 26, 2017

06/28/2017

Quidel Receives FDA Clearance and CLIA Waiver for Its Point-of-Care Sofia® 2 Instrument for Use with Sofia Respiratory Syncytial Virus (RSV) Assay

06/22/2017

Quidel’s Sofia® 2 Point-of-Care Immunoassay Analyzer Receives Multiple Awards from Good Design Australia®’s 2017 Good Design Awards®

06/07/2017

Quidel Receives the CE Mark for Its Thyretain® TBI Reporter BioAssay

05/30/2017

Quidel Receives FDA Clearance and CLIA Waiver for Its Point-of-Care Sofia® 2 Immunoassay Analyzer for Use with Sofia Influenza A+B Assay

05/24/2017

Quidel Receives PMDA Approval for Its Point-of-Care Sofia® Influenza A+B Assay

05/16/2017

Quidel Completes Acquisition of InflammaDry(R) and AdenoPlus(R) Eye-Health Businesses

05/11/2017

Quidel Receives FDA Clearance for Its New Solana(R) Molecular Assay for the Detection of Clostridium difficile (C. difficile) Infections

05/01/2017

Quidel to Present at the Bank of America Merrill Lynch 2017 Health Care Conference

04/24/2017

Quidel Reports First Quarter 2017 Financial Results

04/11/2017

Quidel to Hold First Quarter 2017 Financial Results Conference Call on April 24, 2017

03/02/2017

Quidel to Present at the Barclays Global Healthcare Conference

02/08/2017

Quidel Reports Fourth Quarter and Full Year 2016 Financial Results

01/25/2017

Quidel to Hold Fourth Quarter and Full Year 2016 Financial Results Conference Call on February 8, 2017

01/23/2017

Quidel Announces Modification of Revenue Reporting Categories

01/06/2017

Quidel Announces Preliminary Revenue for Fourth Quarter 2016